8NN.F Nordic Nanovector ASA
- Market cap
- EUR 169M
- P/E
- -
- P/B
- 4.13x
- ROE
- -12.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8NN.F undervalued?
Graham numberThe Graham number of Nordic Nanovector ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nordic Nanovector ASA fundamental analysis
No fundamental analysis for Nordic Nanovector ASA yet.
Nordic Nanovector ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nordic Nanovector ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Full company profileNordic Nanovector ASA financial statements
Nordic Nanovector ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 314K | 302K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439K |
| Gross Profit | - | - | -222M | - | - | - | - | - | - | - |
| Operating Income | -216M | -317M | -340M | -440M | -434M | -442M | 0.00 | -7.16M | -43.9M | -69.7M |
| EBITDA | - | -315M | -338M | -419M | -401M | -428M | 11.2M | -4.84M | -40.2M | -40.7M |
| Net Income | -236M | -294M | -338M | -434M | -417M | -441M | -311M | -26.6M | -42.2M | -58.0M |
| EPS | - | -5.93 | -6.76 | -6.51 | -5.21 | -4.44 | -2.61 | -0.11 | -0.15 | -0.16 |
| Balance Sheet | ||||||||||
| Total Assets | 1.04B | 780M | 474M | 516M | 315M | 297M | 110M | 331M | 414M | 709M |
| Total Liabilities | 95.5M | 101M | 110M | 128M | 136M | 156M | 45.8M | 58.9M | 77.2M | 253M |
| Shareholders' Equity | 949M | 680M | 363M | 388M | 179M | 141M | 63.8M | 272M | 337M | 456M |
| Cash & Short-term Investments | 1.02B | 755M | 439M | 469M | 293M | 277M | 96.6M | 41.3M | 123M | 181M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -204M | -249M | -327M | -411M | -398M | -403M | -409M | -64.1M | -23.7M | -47.5M |
| Capital Expenditure | 1.50M | 2.51M | 2.16M | 1.07M | 185K | 259K | 5.63M | 0.00 | 100K | 73.1M |
| Free Cash Flow | - | -252M | -329M | -412M | -398M | -404M | -415M | -64.1M | -23.8M | -121M |
| Ratios | ||||||||||
| ROE | -24.8% | -43.2% | -93.0% | -111.7% | -233.4% | -314.1% | -487.5% | -9.8% | -12.5% | -12.7% |
| ROA | -22.5% | -37.6% | -71.3% | -84.1% | -132.6% | -148.8% | -283.9% | -8.0% | -10.2% | -8.2% |
| Net Profit Margin | -75,003.2% | -97,289.4% | - | - | - | - | - | - | - | -13,214.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nordic Nanovector ASA dividends
Nordic Nanovector ASA has not paid dividends in the last 10 fiscal years.
Who owns Nordic Nanovector ASA
- Insiders 35.92%
- Institutions 7.25%
- Public & others 56.83%
- Shares outstanding 423M
- Free float 204M
Nordic Nanovector ASA company profile
- Company name
- Nordic Nanovector ASA
- Ticker
- 8NN.F
- ISIN
- NO0010597883
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- December
- Address
- Drammensveien 167, Oslo, Norway, 0277
- Phone
- 47 97 41 40 00
- Website
- thormedical.no
About Nordic Nanovector ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Nordic Nanovector ASA management
6- Mr. Jasper KurthChief Executive Officer · born 1985
- Mr. Brede EllingsæterCFO & COO
- Dr. Sindre HassfjellChief Technology Officer
- Ms. Astrid LilandExecutive Vice President of HSEQ
- Mr. Mathias Nilsen ReierthHead of Communications & Corporate Affairs
- Ms. Therese KvehaugenExecutive Vice President of Human Resources